JP2011521652A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521652A5
JP2011521652A5 JP2011511949A JP2011511949A JP2011521652A5 JP 2011521652 A5 JP2011521652 A5 JP 2011521652A5 JP 2011511949 A JP2011511949 A JP 2011511949A JP 2011511949 A JP2011511949 A JP 2011511949A JP 2011521652 A5 JP2011521652 A5 JP 2011521652A5
Authority
JP
Japan
Prior art keywords
ana
rna
chemically modified
modified sirna
sense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011511949A
Other languages
English (en)
Japanese (ja)
Other versions
JP5684116B2 (ja
JP2011521652A (ja
Filing date
Publication date
Priority claimed from CA002635187A external-priority patent/CA2635187A1/en
Priority claimed from PCT/CA2008/002259 external-priority patent/WO2009076775A1/en
Application filed filed Critical
Publication of JP2011521652A publication Critical patent/JP2011521652A/ja
Publication of JP2011521652A5 publication Critical patent/JP2011521652A5/ja
Application granted granted Critical
Publication of JP5684116B2 publication Critical patent/JP5684116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011511949A 2008-06-05 2009-06-05 Ｄｎａ様ヌクレオチドおよびｒｎａ様ヌクレオチドを含むオリゴヌクレオチド二重鎖およびその使用 Active JP5684116B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5918608P 2008-06-05 2008-06-05
US61/059,186 2008-06-05
CA002635187A CA2635187A1 (en) 2008-06-05 2008-06-17 Oligonucleotide duplexes and uses thereof
CA2,635,187 2008-06-17
CAPCT/CA2008/002259 2008-12-19
PCT/CA2008/002259 WO2009076775A1 (en) 2007-12-19 2008-12-19 Immune response modulation and uses thereof
PCT/CA2009/000789 WO2009146556A1 (en) 2008-06-05 2009-06-05 Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof

Publications (3)

Publication Number Publication Date
JP2011521652A JP2011521652A (ja) 2011-07-28
JP2011521652A5 true JP2011521652A5 (OSRAM) 2014-08-28
JP5684116B2 JP5684116B2 (ja) 2015-03-11

Family

ID=41397419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511949A Active JP5684116B2 (ja) 2008-06-05 2009-06-05 Ｄｎａ様ヌクレオチドおよびｒｎａ様ヌクレオチドを含むオリゴヌクレオチド二重鎖およびその使用

Country Status (6)

Country Link
US (2) US9090649B2 (OSRAM)
EP (1) EP2294195B1 (OSRAM)
JP (1) JP5684116B2 (OSRAM)
CA (2) CA2635187A1 (OSRAM)
ES (1) ES2643576T3 (OSRAM)
WO (1) WO2009146556A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283022B2 (en) 2006-08-08 2011-07-28 Rheinische Friedrich-Wilhelms-Universitat Bonn Structure and use of 5' phosphate oligonucleotides
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
DK2756080T3 (da) 2011-09-14 2019-05-20 Translate Bio Ma Inc Multimeriske oligonukleotidforbindelser
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
AU2013262700A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
CN104540947A (zh) 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节smn基因家族表达的组合物和方法
JP2015518713A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Ｕｔｒｎ発現を調節するための組成物及び方法
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
CA2884608C (en) 2012-09-14 2025-05-20 Translate Bio Ma, Inc. MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP2016534035A (ja) 2013-10-04 2016-11-04 ラナ セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症を治療するための組成物及び方法
EP3212824A4 (en) 2014-10-30 2018-08-08 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
EP4013428A4 (en) * 2019-08-15 2023-08-09 Ionis Pharmaceuticals, Inc. MODIFIED OLIGOMER COMPOUNDS AND USES THEREOF

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6336859B2 (en) * 1993-03-31 2002-01-08 Progressive Games, Inc. Method for progressive jackpot gaming
US7084125B2 (en) * 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US6639059B1 (en) * 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6734291B2 (en) * 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
AU776362B2 (en) * 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
US6338859B1 (en) 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US6780428B2 (en) * 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
IL166546A0 (en) * 2002-08-05 2006-01-15 Atugen Ag Further novel forms of interfering ran molecules
ES2332178T5 (es) 2003-03-21 2014-02-04 Santaris Pharma A/S Análogos de ARN pequeños de interferencia (ARNpi)
US7262253B2 (en) * 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US20090306177A1 (en) * 2005-09-16 2009-12-10 Coley Pharmaceutical Gmbh Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification
EP1945267A2 (en) * 2005-10-28 2008-07-23 Topigen Pharmaceuticals Inc. Small interfering oligonucleotides comprising arabinose modified nucleotides
US20090069263A1 (en) * 2005-12-16 2009-03-12 Damha Masad J 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CN102124107A (zh) 2006-07-17 2011-07-13 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制
CA2699184A1 (en) * 2006-09-22 2008-03-27 Labopharm Inc. Compositions and methods for ph targeted drug delivery
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof

Similar Documents

Publication Publication Date Title
JP2011521652A5 (OSRAM)
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
JP6295232B2 (ja) 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法
WO2007134161A3 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
JP2017079776A5 (OSRAM)
JP2010525813A5 (OSRAM)
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2008116860A3 (en) Dsrna compositions and methods for treating hpv infections
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
JP2018513668A5 (OSRAM)
JP2008283975A5 (OSRAM)
JP2017534285A5 (OSRAM)
Pasternak et al. Unlocked nucleic acid–an RNA modification with broad potential
JP2009514877A5 (OSRAM)
JP2013534424A5 (OSRAM)
JP2007529224A5 (OSRAM)
JP2018512876A5 (OSRAM)
WO2007137156A3 (en) Rnai modulation of aha and therapeutic uses thereof
JP2005500025A5 (OSRAM)
NZ598943A (en) Hbv antisense inhibitors
WO2008022046B1 (en) Dicer substrate rna peptide conjugates and methods for rna therapeutics
NZ599237A (en) Sirna compounds comprising terminal substitutions